Changes to the adult pneumococcal vaccination schedule under the National Immunisation Program from 1 July 2026
From 1 July 2026 there will be changes to the adult pneumococcal vaccination schedule under the National Immunisation Program (NIP). Key changes:
-
21-valent pneumococcal conjugate vaccine (21vPCV), Capvaxive®, will be introduced on the NIP and the adult immunisation schedule updated.
-
Capvaxive® will replace Prevenar 13® and Pneumovax 23® on the NIP for adults.
Capvaxive® is recommended and free through the NIP (from 1 July 2026) for:
-
all people aged 65 years and over – single dose
-
Aboriginal and Torres Strait Islander 25 years and over – single dose
-
People aged 18 years and over with an eligible medical condition* – single dose at diagnosis
*See Australian Immunisation Handbook Table. Risk conditions for pneumococcal vaccination and eligibility for NIP funding
Adult pneumococcal vaccination – Program advice for health professionals
Pneumococcal vaccination – Consumer fact sheet
Further information/resources will be available just prior to the program change on 1 July 2026.
In preparation, providers should:
- limit orders of Prevenar 13 and only keep enough stock for use until the end of June
- register for the NCIRS webinar on 24 June for a practical update on pneumococcal disease in adults and what forthcoming program changes will mean for immunisation providers
- email pcait@snhn.org.au if you would like a printed copy of the new NSW Schedule – include size (A3 or A4) and quantity.